Picky Portfolio

client

Personal Genome Diagnostics (PGDx) is a pioneering force in cancer genomics, dedicated to transforming oncology care through advanced, precision-based solutions. By providing clinicians with actionable genomic insights, they enable personalized cancer treatments that are tailored to each patient’s unique profile. Their innovative approach bridges the gap between cutting-edge genomic research and real-world clinical application, ensuring that every patient has access to the most effective, data-driven treatment options available.

client

Personal Genome Diagnostics (PGDx) is a pioneering force in cancer genomics, dedicated to transforming oncology care through advanced, precision-based solutions. By providing clinicians with actionable genomic insights, they enable personalized cancer treatments that are tailored to each patient’s unique profile. Their innovative approach bridges the gap between cutting-edge genomic research and real-world clinical application, ensuring that every patient has access to the most effective, data-driven treatment options available.

client

Personal Genome Diagnostics (PGDx) is a pioneering force in cancer genomics, dedicated to transforming oncology care through advanced, precision-based solutions. By providing clinicians with actionable genomic insights, they enable personalized cancer treatments that are tailored to each patient’s unique profile. Their innovative approach bridges the gap between cutting-edge genomic research and real-world clinical application, ensuring that every patient has access to the most effective, data-driven treatment options available.

focus

PGDx sought to broaden their services beyond their traditional biopharma focus, introducing a diverse range of kitted solutions for pathologists and oncologists. They needed a clear and compelling way to communicate the advantages of improved patient care, data ownership, and the financial opportunities associated with these new offerings.

focus

PGDx sought to broaden their services beyond their traditional biopharma focus, introducing a diverse range of kitted solutions for pathologists and oncologists. They needed a clear and compelling way to communicate the advantages of improved patient care, data ownership, and the financial opportunities associated with these new offerings.

focus

PGDx sought to broaden their services beyond their traditional biopharma focus, introducing a diverse range of kitted solutions for pathologists and oncologists. They needed a clear and compelling way to communicate the advantages of improved patient care, data ownership, and the financial opportunities associated with these new offerings.

result

Along with my team at Audacity Health, I helped PGDx evolve their corporate brand ahead of the re-launch of PGDx elio™ tissue complete. Through patient-focused and mission-driven concepts, we emphasized the benefits of using unique biomarkers for improved cancer care and highlighted PGDx's scalable technology that transforms global cancer treatment. I created custom iconography, a brand guide, promotional collateral, and contributed to the design of a new website that effectively communicated the value of CGP for both in-house integration and biopharma partnerships. The re-launch led to a successful international debut of the new kitted solution and a stronger corporate identity, which endured after PGDx's 2022 acquisition by Labcorp.

result

Along with my team at Audacity Health, I helped PGDx evolve their corporate brand ahead of the re-launch of PGDx elio™ tissue complete. Through patient-focused and mission-driven concepts, we emphasized the benefits of using unique biomarkers for improved cancer care and highlighted PGDx's scalable technology that transforms global cancer treatment. I created custom iconography, a brand guide, promotional collateral, and contributed to the design of a new website that effectively communicated the value of CGP for both in-house integration and biopharma partnerships. The re-launch led to a successful international debut of the new kitted solution and a stronger corporate identity, which endured after PGDx's 2022 acquisition by Labcorp.

result

Along with my team at Audacity Health, I helped PGDx evolve their corporate brand ahead of the re-launch of PGDx elio™ tissue complete. Through patient-focused and mission-driven concepts, we emphasized the benefits of using unique biomarkers for improved cancer care and highlighted PGDx's scalable technology that transforms global cancer treatment. I created custom iconography, a brand guide, promotional collateral, and contributed to the design of a new website that effectively communicated the value of CGP for both in-house integration and biopharma partnerships. The re-launch led to a successful international debut of the new kitted solution and a stronger corporate identity, which endured after PGDx's 2022 acquisition by Labcorp.